Vinorelbine (Navelbine) in the treatment of non-small-cell lung cancer: studies with single-agent therapy and in combination with cisplatin.

Abstract

Initial studies of vinorelbine (Navelbine) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be obtained with a schedule of 30 mg/m2 given weekly. Although such high levels of response have seldom been obtained when vinorelbine is given alone in one arm of a… (More)

Topics

Cite this paper

@article{Gralla1999VinorelbineI, title={Vinorelbine (Navelbine) in the treatment of non-small-cell lung cancer: studies with single-agent therapy and in combination with cisplatin.}, author={R Gralla and Peter G. Harper and Sarah Johnson and F. M. Delgado}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={1999}, volume={10 Suppl 5}, pages={S41-5} }